Please login to the form below

Not currently logged in
Email:
Password:

Kite

This page shows the latest Kite news and features for those working in and with pharma, biotech and healthcare.

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma

First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent ... Kite also recently revealed some positive data for

Latest news

More from news
Approximately 20 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene

  • Deal Watch October 2018

    Gilead’s subsidiary, Kite, has agreed a deal for a research collaboration with HiFiBiO Therapeutics, the Hong Kong-based company which is working on the discovery of therapeutic antibodies through single

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark has signed a marketing deal with Novartis in Europe, which means the big pharma company will set the

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.

  • How do you define a biotech company?

    This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where 

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics